IP Library Granted Patent US 8,455,016
Granted Patent B2
US 8,455,016 · App. 12/780,730 · Granted Jun 4, 2013

Treatment for meibomian gland dysfunction or obstruction

Inventor: Steven Maskin (Tampa, FL)
Assignee: MELBJ Holdings, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,016
App. No.
12/780,730
Granted
Jun 4, 2013
Kind
B2
Abstract

A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and/or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent.

Claims (5)

1. A sterile ophthalmic ointment or cream for administration to the eye comprising an effective amount of an aqueous emulsion of jojoba wax or jojoba wax ester and/or alcohol esterified with long chain fatty acids with a total of 12 to 62 carbon atoms as a starting material to form the ointment or cream, to penetrate the lid margin and reduce meibomian gland obstruction, wherein the concentration of the jojoba wax or jojoba wax ester and/or alcohol is between 5% and 50% by weight of the ointment or cream.

2. The ointment or cream of claim 1 , wherein the ointment or cream base is a semi-solid selected from the group consisting of a mixture of mineral oil and petrolatum in a ratio of about 70% to 30%, paraffin up to 5% of the ointment or cream base, white ointment up to 100% of the ointment or cream base, white petrolatum up to 100% of the ointment or cream base, petrolatum up to 100% of the ointment or cream base, white wax up to 5% of the ointment or cream base, yellow wax up to 5% of the ointment or cream base, mineral oil up to 50% of the ointment or cream base, light mineral oil up to 50% of the ointment or cream base, lanolin 1 to 10% of the ointment or cream base, and anhydrous lanolin 1 to 10% of the ointment or cream base.

3. The ointment or cream of claim 1 comprising a local anesthetic.

4. The ointment or cream of claim 3 comprising from 2 to 20% Lidocaine by weight of the ointment or cream.

5. The ointment or cream of claim 4 comprising 8% lidocaine and 25% Jojoba by weight of the ointment or cream in a petrolatum ointment base.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2020
From: MELBJ HOLDINGS LLC
To: MGD INNOVATIONS, INC.
Reel/Frame 052658/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2010
From: MASKIN, STEVEN
To: MELBJ HOLDINGS, LLC
Reel/Frame 024545/0663 →
Continuity (4)
Continuation In Part 11069239 · Mar 1, 2005
Provisional Application 60552577 · Mar 12, 2004
Provisional Application 60562683 · Apr 15, 2004
Related Publication 20110124725A1 · May 26, 2011